At anticonvulsant doses (1000-3000 mg/day):

• Fatigue / somnolence — most common subjective effect, especially first 2-4 weeks.
• Mental dulling / "Keppra fog" — slowed processing, reduced verbal fluency, harder word retrieval, attention slippage. Variable across users.
• Asthenia — physical tiredness, lower exercise tolerance.
• Emotional blunting — reduced range of affect, sometimes reported as "numbness" or "flatness."
• Keppra rage (~10-20% of users) — irritability, anger outbursts, frustration tolerance collapse, anxiety, depression, suicidal ideation. Onset typically within first 4-8 weeks. Often dose-dependent. This is the dominant discontinuation reason in epilepsy practice, despite the otherwise-clean PK and side-effect profile.

At Bakker-research dose (125 mg BID):

• AE profile is substantially milder at this dose, but not absent.
• Subjective cognitive effects in the trial populations: minimal (the cognitive benefit was task-performance-detectable, not subjectively obvious).
• Keppra-rage signal at 125 mg BID is lower than at 1000+ mg/day but still present — psychiatric AEs scale with dose but do not vanish at sub-therapeutic-AED doses.

Honest summary: Even at the lowest research dose, levetiracetam does not produce a subjectively noticeable nootropic effect in healthy users. The subjective experience is "neutral if you're lucky, dulling if you're not, rageful / depressed if you're unlucky."

• Tolerance buildup: Minimal for the seizure-suppression effect. Levetiracetam is one of the more durable AEDs across years of use.
• Cognitive AE tolerance: Some users report cognitive blunting partially abates over weeks-to-months; psychiatric AEs (Keppra rage) generally do not abate without dose reduction or discontinuation.
• Recommended cycle: Not applicable — not a nootropic. Clinical use is continuous; chronic use over years is standard.
• Discontinuation: Should be tapered over 2-4 weeks if used clinically (abrupt cessation can precipitate withdrawal seizures in epilepsy patients). At sub-AED doses (125 mg BID), abrupt cessation is generally tolerated.

Synergistic with

• Other AEDs (clinically — for refractory epilepsy). Not relevant for nootropic context.
• Vitamin B6 (pyridoxine) 50-100 mg/day (if ever used) — reported to reduce Keppra-rage incidence in pediatric literature; mechanism unclear. Worth mentioning for completeness.

Avoid stacking with

• piracetam, oxiracetam, aniracetam, pramiracetam, phenylpiracetam, coluracetam — not because of pharmacological interaction (the mechanisms don't conflict), but because stacking an anticonvulsant with cognitive enhancers makes no sense: the cognitive racetams modestly increase glutamatergic signaling (the direction you want for cognitive output), while levetiracetam dampens presynaptic release (the opposite direction). If both have effects, they at least partially cancel; if one dominates, it's almost certainly the SV2A dampening (which is the unwanted direction for nootropic use).
• brivaracetam — mechanistically similar (~15-30× higher SV2A affinity); same concerns at higher potency. No reason to stack two SV2A ligands.
• CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines) — additive somnolence / sedation. Dylan: zero alcohol baseline, so this is a non-issue, but worth noting if context ever changes.
• Other AEDs without clinical reason — polypharmacy AED exposure increases AE risk without benefit outside epilepsy management.

Neutral / safe co-administration

• V4 supplement core (DHA, Mg threonate, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C) — no known interactions. Levetiracetam's clean PK (no CYP) means most supplement interactions are minimal.
• Modafinil — no PK interaction; opposing effects (modafinil pro-cognitive, levetiracetam neutral-to-blunting); no reason to combine.
• Caffeine, theanine — no interaction.
• Creatine — no interaction.

One of the cleanest CYP-interaction profiles in modern pharmacology — this is a major clinical advantage in epilepsy polypharmacy contexts and a property that makes Bakker-line research feasible.

• No significant CYP induction or inhibition. Levetiracetam does not affect CYP1A2, 2C9, 2C19, 2D6, 2E1, 3A4 to any clinically meaningful degree.
• Hormonal contraceptives: No interaction. Unlike older AEDs (carbamazepine, phenytoin, phenobarbital), levetiracetam does not reduce oral contraceptive efficacy.
• Warfarin: No PK interaction; no INR adjustment needed.
• Other AEDs: Phenytoin, valproate, carbamazepine — no significant PK interactions in either direction.
• Probenecid: Reduces levetiracetam clearance ~20% (via tubular-secretion competition). Not clinically significant for most uses.
• Renal-clearance drugs: Any drug that significantly impairs renal function increases levetiracetam exposure (NSAIDs, ACE inhibitors at high doses, contrast media in vulnerable patients).

Practical implication: If levetiracetam ever became indicated for Dylan (clinical, not nootropic), it would be one of the most "stackable" AEDs in terms of not disturbing other medications. This same property is why it's a reasonable research drug at low doses for the Bakker line — minimal interaction risk.

Limited pharmacogenomic data on levetiracetam — most of the variability is pharmacodynamic (response variability, AE susceptibility) rather than pharmacokinetic (since metabolism is non-CYP).

• SV2A polymorphisms — some reports of variation in SV2A expression / sequence affecting levetiracetam response in epilepsy. Not clinically actionable as of 2026.
• 23andMe-detectable variants: No high-confidence levetiracetam response markers in the standard 23andMe panel.
• Psychiatric AE susceptibility: Patients with prior psychiatric history (depression, anxiety, ADHD, prior suicidality) are at substantially higher risk for Keppra rage. This is a clinical-history risk factor, not a genetic one.
• Pediatric vs. adult metabolism: Children clear levetiracetam faster (mg/kg basis) than adults; not relevant for Dylan-archetype.

For Dylan: 23andMe (results due ~June 5-15, 2026) is unlikely to surface levetiracetam-relevant findings. The compound is not pharmacogenomically gated for him in any actionable way.

Sourcing-difficulty: easy. The compound is universally available at low cost. The barrier is not sourcing — it's the lack of indication.

(Listed for completeness; not relevant for Dylan barring an indication change.)

• Baseline (before starting, if ever): CBC with differential, BMP/CMP (creatinine, eGFR, sodium), liver panel, baseline mood screens (PHQ-9, GAD-7), seizure history, prior psychiatric history, baseline cognitive profile (since blunting is a known AE).
• During use:
  • eGFR every 3-6 months (renal clearance dictates dosing).
  • PHQ-9 / GAD-7 monthly for first 3 months, then quarterly (psychiatric AE monitoring).
  • Behavioral / irritability tracking by self-report and partner-report (Keppra rage often noticed by family before patient).
  • CBC at 3 months, then annually (rare hematologic AEs).
  • Sodium check if clinically indicated (rare hyponatremia).
• Post-discontinuation: If used clinically, taper monitoring; mood normalization typically within 2-4 weeks of full discontinuation.